Probiotics are live microorganisms — mostly bacteria from the Lactobacillaceae family (species formerly grouped under Lactobacillus) and Bifidobacterium, and sometimes yeasts such as Saccharomyces boulardii — that, per the International Scientific Association for Probiotics and Prebiotics definition cited by NIH ODS, "when administered in adequate amounts, confer a health benefit on the host." They occur naturally in some fermented foods (notably yogurt) and are sold as dietary supplements in capsules, powders, and liquids. Each is identified by genus + species + strain (for example, Lacticaseibacillus rhamnosus GG, known as "LGG"), and the number of live cells is measured in colony-forming units (CFU). They are NOT FDA-approved to treat any disease, and NIH ODS cautions that not all foods and products labeled "probiotic" actually have proven health benefits.
Probiotics are marketed as an everyday essential for "gut health," "immune support," bloating, and "balancing your microbiome" — a multi-billion-dollar category sold as general wellness insurance. The government-authority read is far more restrained. NCCIH states plainly that "in most instances, we still don't know which probiotics are helpful and which are not," and that clear answers are missing on which strains work, at what dose, and for whom. The single most important and most-ignored fact is that benefits are STRAIN-SPECIFIC: NCCIH warns that if a specific kind of Lactobacillus helps prevent an illness, "that doesn't necessarily mean that another kind of Lactobacillus or any of the Bifidobacterium probiotics would do the same thing." NIH ODS adds that the effects of many commercial products have never been examined in studies and that a higher CFU count is not necessarily more effective. Probiotics are dietary supplements, not FDA-approved drugs, and cannot legally claim to treat disease; NCCIH also notes some products have been found to contain microorganisms other than those listed on the label.
Antibiotics disrupt gut bacteria, and NIH ODS notes up to 30% of people who take them develop diarrhea. NCCIH cites a 2017 review finding probiotics 'associated with a decrease of about half in the likelihood' of AAD (moderate-quality evidence), and NIH ODS reports meta-analyses of about a 51% risk reduction — but only with specific strains (Lactobacillus rhamnosus GG or Saccharomyces boulardii), started within 2 days of the first antibiotic dose, and mainly in children and adults age 18-64. A benefit was NOT demonstrated in adults 65 and older.
NCCIH cites a 2017 analysis (31 studies) that concluded 'it is moderately certain that probiotics can reduce the risk of C. difficile diarrhea in adults and children who are receiving antibiotics.' This is prevention taken alongside antibiotics, not treatment of an established C. diff infection, and NCCIH stresses the optimal strains, duration, and dosages are uncertain — and that safety is unclear in patients who are severely ill or have poorly functioning immune systems, the same frail group at highest risk of C. diff.
NCCIH cites a 2018 review concluding probiotics 'may have beneficial effects on global IBS symptoms and abdominal pain,' but that 'it was not possible to draw definite conclusions.' NIH ODS reports most meta-analyses find a positive but MODEST effect (one 23-trial, 2,575-patient analysis cut the risk of persistent symptoms by about 21%) while rating study quality low, with effects depending on the specific strain and symptom; multi-strain products fared somewhat better in some analyses. Reasonable to trial, not a reliable fix.
A 2020 Cochrane Review (82 RCTs, ~12,000 people, mostly children) cited by NIH ODS found probiotics cut the risk of diarrhea lasting 48 hours or more by 36% and shortened it by about 21 hours — but when only low-risk-of-bias studies were pooled, that benefit disappeared. Reflecting this, the American Gastroenterological Association recommends AGAINST probiotics for acute infectious gastroenteritis in children in the US and Canada, where most cases are self-limiting and need only rehydration.
There is no authority recommendation for routine probiotic use in healthy people. NIH ODS states plainly that 'there are currently no formal recommendations for or against the use of probiotics in healthy people' and that expert bodies of health professionals 'make no recommendations for or against the use of probiotics by healthy people.' NCCIH provides no evidence supporting general digestive-wellness claims. The 'balance your gut' marketing runs well ahead of the science.
NCCIH notes that people taking probiotics 'may have fewer and shorter' upper-respiratory infections, but that 'the quality of the evidence was low.' There is no solid evidence that probiotics broadly strengthen immunity or prevent illness in otherwise healthy people, and the NIH ODS probiotics fact sheet addresses respiratory infections only by pointing to a separate immune-function fact sheet. A low-quality signal, not an established benefit.
There is no official or FDA-set dose, and because effects are strain-specific, doses are NOT interchangeable between products. NIH ODS notes probiotics are measured in colony-forming units (CFU): many supplements contain 1-10 billion CFU per dose and some 50 billion or more, but a higher CFU count is not necessarily more effective. For the best-supported use — preventing antibiotic-associated diarrhea — trials used specific strains at specific timing: the ESPGHAN working group suggests 5 billion CFU/day or more of Lactobacillus rhamnosus GG or Saccharomyces boulardii, started at the same time as the antibiotic (within 2 days) and continued through the course; LGG at roughly 1-2 x 10^10 CFU/day reduced children's AAD risk by about 71%. Because live cells die during shelf life, NIH ODS advises choosing products labeled with the CFU count through the expiration or use-by date (not "at time of manufacture") and following storage instructions, since some require refrigeration. This is general information per ODS/NCCIH, not personalized dosing advice.
For most healthy people, common probiotics (Lactobacillaceae and Bifidobacterium) are unlikely to cause harm, and side effects are usually minor and self-limited — mainly gas and mild digestive upset (NIH ODS). But NCCIH notes safety has not been studied in detail, and the risks are real in specific groups. SERIOUS INFECTION RISK: NIH ODS documents cases of bacteremia (bacteria in the blood), fungemia (fungi in the blood), and severe infections — most involving people who were severely ill or immunocompromised; at least 60 fungemia reports since 1966 are linked to Saccharomyces-containing probiotics, often in ICU patients with a central venous catheter or on tube/IV feeding, and one Boston hospital analysis of 22,174 ICU patients found those given LGG by feeding tube had a markedly higher risk of Lactobacillus bloodstream infection. PREMATURE INFANTS: The FDA warned in 2023 that giving probiotics to preterm infants risks "invasive, potentially fatal disease," after a preterm infant given a probiotic developed Bifidobacterium longum sepsis and died; the FDA stresses no probiotic is approved as a drug for infants and these products are not tested for extraneous organisms. WHO SHOULD AVOID or get medical clearance first: people who are immunocompromised, critically ill, or have serious underlying illness (the World Gastroenterology Organisation advises limiting use to strains proven for that condition); anyone with a central venous catheter or on tube/IV feeding; and premature infants. PRODUCT-QUALITY RISK: NCCIH warns some products have contained microorganisms other than those on the label, and other possible harms include production of harmful substances by the microorganisms and transfer of antibiotic-resistance genes. If you take antibiotics or have any serious health condition, tell your clinician before adding a probiotic.
Probiotics are strain-specific tools, not a general wellness cure — the same-looking capsule can help one problem and do nothing for another. The honest evidence is best for preventing antibiotic-associated diarrhea (with specific strains like Lactobacillus rhamnosus GG or Saccharomyces boulardii, started early), and NCCIH calls it "moderately certain" that probiotics can reduce the risk of C. difficile diarrhea when taken alongside antibiotics. For IBS the benefit is modest and inconsistent; for shortening a stomach bug the evidence is mixed and US guidelines advise against it in children; and for everyday "gut health" or "immune-boosting" in healthy people there is no authority recommendation and no solid evidence. If you try one, match the specific strain and dose to a use that has actually been studied, choose a product that lists live CFU through its expiration date, and remember probiotics are not FDA-approved to treat any disease. People who are immunocompromised, critically ill, have a central line, or are caring for a premature infant should not use probiotics without medical guidance because of a real risk of serious infection. This is general information, not medical advice — talk to your doctor or pharmacist before starting, especially if you have a health condition or take other medicines.
Supplement quality varies by manufacturer — favor third-party-tested brands (NSF, USP Verified, Informed Sport) and compare prices before buying.
Compare probiotics prices on Amazon ↗Advertising disclosure: Some links are affiliate links. We may earn a commission at no extra cost to you. This never affects our independent ratings.
General information, not medical advice. Dietary supplements are not FDA-approved to treat, cure, or prevent any disease, and quality/purity vary by brand. Talk to your clinician or pharmacist before starting one — especially if you’re pregnant, breastfeeding, or take other medicines.